Reuters logo
BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial
November 16, 2017 / 9:17 PM / a month ago

BRIEF-Aerie Pharma initiates netarsudil ophthalmic solution Phase 2 clinical trial

Nov 16 (Reuters) - Aerie Pharmaceuticals Inc

* Aerie Pharmaceuticals initiates netarsudil ophthalmic solution Phase 2 clinical trial designed to meet requirements of regulatory filing in Japan

* Aerie Pharmaceuticals Inc - ‍for Rhopressa, U.S. FDA PDUFA goal date of February 28, 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below